Yazar "Akay, Olga Meltem" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study
    (Cig Media Group, Lp, 2021) Ozbalak, Murat; Akay, Olga Meltem; Pehlivan, Mustafa; Yildiz, Birol; Uzay, Ant; Yigenoglu, Tugce Nur; Elverdi, Tugrul
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study
    (Wiley, 2021) Akay, Olga Meltem; Özbalak, Murat; Pehlivan, Mustafa; Yıldız, Birol; Uzay, Ant; Yiğenoğlu, Tuğçe Nur; Elverdi, Tuğrul; Ayyıldız, Orhan; 0000-0002-6759-1939; 0000-0002-3040-4052; 0000-0002-6692-085X; 0000-0003-1381-4188; 0000-0001-9962-8882; 0000-0001-5673-8408
    The AETHERA trial reported an increased progression-free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high-risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Thus, we aimed to determine the impact and safety of BV as maintenance after ASCT in real-world patients. Seventy-five patients with relapsed/refractory HL started on BV consolidation therapy after ASCT due to high risk of relapse, between January 2016 and July 2019, from 25 institutions, were included in the study. The median follow-up time was 26 months. The most common high-risk features were primary refractory or relapsed disease <12 months (n = 61), lack of complete response (CR) to the last salvage regimen (n = 51), and having had at least two salvage regimens (n = 29). At the time of analysis, 42 patients completed consolidation courses, and BV was discontinued in 33 patients. Fifty patients had an ongoing response (CR in 41, PR in 6, and SD in 3 patients), 25 had progressed. Ten died in the follow-up, eight with progressive disease and two due to infection while in CR. The 2-year PFS and OS rates were 67.75% (95% confidence interval [CI]: 0.55-0.77) and 87.61% (95% CI: 0.76-0.94), respectively. Seventeen patients (23%) received BV in the pre-ASCT treatment lines, and there was no survival difference between the BV-naive and BV-exposed groups. The most common adverse events were neutropenia (27%) and peripheral neuropathy (21%). Sixteen patients (21.3%) experienced grade 3 or 4 toxicity. BV was discontinued due to adverse event in 12 patients. Consolidation with BV after ASCT can achieve a 2-year PFS of 67.75% (95% CI: 0.55-0.75) with an acceptable toxicity profile.
  • Küçük Resim
    Öğe
    Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience
    (Springer, 2021) Şahin, Deniz Gören; Akay, Olga Meltem; Keklik, Muzaffer; Okan, Vahap; Karakuş, Abdullah; Demir, Cengiz; Erkurt, Mehmet Ali; İlkkılıç, Kadir; Yıldırım, Rahşan; Çağlıyan, Gülsüm Akgün; Aksu, Salih; Doğu, Mehmet Hilmi; Dal, Mehmet Sinan; Karakuş, Volkan; Gemici, Ali İhsan; Terzi, Hatice; Kelkitli, Engin; Şıvgn, Serdar; Ünal, Ali; Yılmaz, Mehmet; Ayyıldız, Orhan; Korkmaz, Serdal; Eser, Bülent; Altuntaş, Fevzi
    The aim of this study is to collect paroxysmal nocturnal hemoglobinuria (PNH) patient data from hematology centers all over Turkey in order to identify clinical features and management of PNH patients. Patients with PNH were evaluated by a retrospective review of medical records from 19 different institutions around Turkey. Patient demographics, medical history, laboratory findings, and PNH-specific information, including symptoms at the diagnosis, complications, erythrocyte, and granulocyte clone size, treatment, and causes of death were recorded. Sixty patients (28 males, 32 females) were identified. The median age was 33 (range; 17-77) years. Forty-six patients were diagnosed as classic PNH and 14 as secondary PNH. Fatigue and abdominal pain were the most frequent presenting symptoms. After eculizumab became available in Turkey, most of the patients (n = 31/46, 67.4%) were switched to eculizumab. Three patients with classic PNH underwent stem cell transplantation. The median survival time was 42 (range; 7-183 months) months. This study is the first and most comprehensive review of PNH cases in Turkey. It provided us useful information to find out the differences between our patients and literature, which may help us understand the disease.